Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

This study is testing the weight-loss drug tirzepatide (a weekly injection that regulates blood sugar and appetite) in people with early-stage hormone receptor-positive, HER2-negative breast cancer. Researchers want to see whether losing weight through tirzepatide reduces the levels of cancer-related hormones and inflammatory markers that can drive breast cancer growth, potentially lowering recurrence risk. **You may be eligible if...** - You are 18 or older (any gender) - You have been diagnosed with hormone receptor-positive (ER or PR >10%), HER2-negative breast cancer - Your cancer was confirmed by biopsy - You are overweight or obese (your doctor will assess BMI eligibility) - You have completed primary cancer treatment **You may NOT be eligible if...** - You have metastatic (stage 4) breast cancer - You have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2) - You are pregnant or breastfeeding - You have severe kidney or gastrointestinal disease that would make tirzepatide unsafe Talk to your doctor to see if this trial is right for you.